drugset / Trial / NCT00924911

Relative Bioavailability Study in Healthy Subjects

NCT00924911

Phase 1 Completed 20 enrolled GlaxoSmithKline
RandomizedCrossoverOpen-labelTreatment

Summary

Part 1 of this study will assess the relative bioavailability of GSK1322322 administered as one of three investigational tablets compared to powder in a bottle formulation. Pharmacokinetics of these three tablets will be evaluated and the investigation tablet with the optimal PK profile will be progressed to Part 2. In Part 2 the investigational tablet selected from Part 1 will be coadministered with food alone, an H2 blocker alone, or an H2 blocker given in combination with ascorbic acid to evaluate the effect on GSK1322322 pharmacokinetics. Plasma GSK1322322 PK profile, safety, and tolerability will be assessed from each dose group.

Timeline

Start
2009-04-27
Primary completion
2009-07-09
Completion
2009-07-09

Drugs

EvaluationDrugModalityDoseRoute
Subject LANOPEPDEN Small molecule 1000 mg